Fig. 5From: Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical programChange from baseline in systolic blood pressure at Week 40 by quartile of baseline value. Data are mean ± SE. Data taken from the safety population of SURPASS 1–5 pooled. N population size, SBP systolic blood pressure, SD standard deviation, TZP tirzepatideBack to article page